GSKH vs. CNCR

Last updated Jun 6, 2026

GSKH (GSK plc ADRhedged ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - GSKH tracks the GSK plc Local Shares Total Return while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. GSKH charges 0.19%/yr vs 0.79%/yr for CNCR.

Performance

GSKH vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GSK plc ADRhedged ETF (GSKH) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

GSKH

• 1D: 1.34%
• 1M: 4.57%
• YTD: 7.84%
• 6M: 8.19%
• 1Y: 30.78%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GSKH vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
GSKH GSK plc ADRhedged ETF	-11.18%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

GSKH vs. CNCR - Sectors Allocation Comparison

Sectors	GSKH	CNCR
Healthcare	100.0%	96.6%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

GSKH vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSKH

GSKH Risk / Return Rank: 36
GSKH Sharpe Ratio Rank: 36
GSKH Sortino Ratio Rank: 39
GSKH Omega Ratio Rank: 38
GSKH Calmar Ratio Rank: 37
GSKH Martin Ratio Rank: 30

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSKH vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GSK plc ADRhedged ETF (GSKH) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GSKH	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	1.18	—	—
Sortino ratio: Return per unit of downside risk	1.82	—	—
Omega ratio: Gain probability vs. loss probability	1.23	—	—
Calmar ratio: Return relative to maximum drawdown	1.67	—	—
Martin ratio: Return relative to average drawdown	4.06	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	GSKH	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.18	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	1.19	—	—

Drawdowns

GSKH vs. CNCR - Drawdown Comparison

The maximum GSKH drawdown since its inception was -18.54%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for GSKH and CNCR.

Drawdown Indicators

	GSKH	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-18.54%	0.00%	-18.54%
Max Drawdown (1Y) Largest decline over 1 year	-18.54%	—	—
Current Drawdown Current decline from peak	-13.28%	0.00%	-13.28%
Average Drawdown Average peak-to-trough decline	-5.65%	0.00%	-5.65%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.61%	—	—

Volatility

Volatility by Period

	GSKH	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.33%	—	—
Volatility (6M) Calculated over the trailing 6-month period	18.35%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	26.30%	0.00%	+26.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	27.08%	0.00%	+27.08%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.08%	0.00%	+27.08%

GSKH vs. CNCR - Expense Ratio Comparison

GSKH has a 0.19% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

GSKH vs. CNCR - Dividend Comparison

GSKH's dividend yield for the trailing twelve months is around 1.57%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%
GSKH GSK plc ADRhedged ETF	1.57%	1.15%

Frequently Asked Questions

Which ETF is better, GSKH or CNCR?

On fees, GSKH is cheaper at 0.19% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, GSKH or CNCR?

GSKH is cheaper with a 0.19% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, GSKH or CNCR?

GSKH has the higher dividend yield at 1.57%, compared with 0.00% for CNCR.

What is the main difference between GSKH and CNCR?

GSKH tracks GSK plc Local Shares Total Return, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: ADRhedged and Exchange Traded Concepts. Their fees differ too: 0.19% for GSKH and 0.79% for CNCR.